8 recruiting. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 8 |
| Phase 1 | 1 | Recruiting 1 |
Follow Dyspnea: new trials by email Literature Review of Dyspnea trials Research Report on Dyspnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of L-menthol on Breathlessness in Asthma L-menthol, Placebo - Asthma | Phase 2 | Recruiting | Region Skane | 20 | 2026-05-07 | 2026-08-19 |
| Efficacy of L-menthol on Breathlessness in Interstitial Lung Disease L-menthol, Placebo - Interstitial Lung Disease (ILD) | Phase 2 | Recruiting | Region Skane | 20 | 2026-04-13 | 2026-04-24 |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma PF-07275315, Placebo - Asthma | Phase 2 | Recruiting | Pfizer | 252 | 2025-05-20 | 2026-10-13 |
| Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology SPOT-ON Early Start, SPOT-ON Delayed Start - Dyspnea | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 150 | 2024-06-11 | 2026-09-24 |
| Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH Tadalafil, Placebo - Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension | Phase 2 | Recruiting | VA Office of Research and Development | 126 | 2024-04-01 | 2026-05-15 |
| 129Xe MRI Cardiopulmonary Hyperpolarized Xe129, Oxygen Administration - Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension | Phase 2 | Recruiting | Bastiaan Driehuys | 125 | 2024-01-12 | 2026-02-04 |
| Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness TRIXEO AEROSPHERE - Copd | Phase 1 / Phase 2 | Recruiting | University Hospital, Lille | 35 | 2023-09-29 | 2025-12-18 |
| Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD Sildenafil Citrate, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | University of Alberta | 160 | 2022-03-01 | 2026-07-08 |
Pulmonary Disease, Chronic Obstructive (3) · Asthma (2) · Lung Diseases, Interstitial (2) · Motor Activity (2) · Airway Obstruction (1) · Anemia (1) · Cigarette Smoking (1) · Hypertension, Pulmonary (1) · Lung Diseases (1) · Polycythemia (1) · Respiratory Hypersensitivity (1) · Respiratory Sounds (1) · Respiratory Tract Diseases (1)
Pathological Conditions, Signs and Symptoms (8) · Respiration Disorders (8) · Signs and Symptoms (8) · Signs and Symptoms, Respiratory (8) · Respiratory Tract Diseases (7) · Lung Diseases (6) · Lung Diseases, Obstructive (5) · Chronic Disease (3) · Disease Attributes (3) · Pathologic Processes (3) · Behavior (2) · Bronchial Diseases (2) · Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2)
Menthol (2) · Oxygen (1) · Sildenafil Citrate (1) · Tadalafil (1)
Region Skane (2) · Bastiaan Driehuys (1) · M.D. Anderson Cancer Center (1) · Pfizer (1) · University Hospital, Lille (1) · University of Alberta (1) · VA Office of Research and Development (1)
United States (4) · Sweden (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Hungary (1) · Italy (1) · Japan (1) · Poland (1) · South Africa (1) · South Korea (1)
David Hui, MD (1) · Joseph Mammarappallil, MD (1) · Michael K Stickland, Ph.D. (1) · Sharon I Rounds, MD (1) · Zainab Ahmadi (1)
I01CX002543 (1)